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Scientists and journalists don’t
always see the world the same way.
A “first” often makes news. But in
science, the “second” – that is the
confirmation – may actually be more
important. Journalists are like
toddlers, though, when it comes to
seconds. They often need coaxing.
Consider two recent cases. 
First, Neanderthal DNA. Back in
1997, reporters made a bit of a fuss
when scientists announced that they
had extracted DNA from
Neanderthal remains for the first
time. In late March, Nature
published a second such find. A
News and Views comment
accompanying the story made a
strong argument that the second
find was scientifically more
interesting than the first. It not only
provided much welcomed
corroboration, given how prone to
error the technology is, but the
discovery opened up the prospect of
a whole new discipline – Neanderthal
genetics – assuming, of course, that
more genetic material would
be forthcoming. 
Cerebral science writers mused
over this story, but had to find a
better angle than the actual
scientific value – that is, the
confirmation that the first find was
genuine. That simply wasn’t grabby.
Instead, reporters settled on a
sub-plot: the new find suggests that
humans and Neanderthals did not
interbreed, as some researchers had
argued of late. 
That was a reasonable tidbit to
report – and for editors to bury, with
headlines such as “Study Challenges
Neanderthal Link” (USA Today,
page 7), or “Neanderthals Ruled
Out” (Daily Telegraph, page 5). Well,
not all news, and especially science
news, can fit on page 1. 
In the second example, readers
around the globe woke up the
morning of March 15 to page 1 news
about something that wasn’t a first. It
wasn’t even a second or a third. The
fourth mammal to be cloned still
managed to grab attention, thanks to
a carefully orchestrated media
release, cute and cuddly pictures (a
sure draw for TV), endearing names
and abundant claims of good health
and good fortune. 
“Five little piggies are going into
the record books as the first of their
species to be cloned,” the New York
Daily News reported, “bringing ever
closer the possibility of animal-
to-human transplantation.” Officials
from PPL Therapeutics, the
company that produced the pigs at
its research center in Virginia, were
downright exuberant about the
prospects in news interviews. “An
end to the chronic organ shortage is
now in sight,” Ron James, managing
director of the company told the
Irish Times, among others. 
“The fourth mammal to be cloned
still managed to grab attention”
PPL Therapeutics announced their
achievement by press release, ten
days after the five piglets were
born. Sticklers for peer review may
have grumbled a bit, but
stockholders didn’t – the value of a
share in the company jumped
19 percent in a day. 
On ABC’s World News Tonight,
PPL Therapeutics Vice President
David Ayares boasted, “we’re going
to be able to revolutionize the
transplant field, and in the near
term, be able to solve the
worldwide organ shortage crisis.” As
US News and World Report
proclaimed: “Not since E.B. White’s
pig Wilbur, has a lowly swine been
so celebrated.” Even the pigs’
names were cute – Dotcom was
so-named because “Any association
with dotcoms right now seems to
have a very positive influence on a
company’s valuation,” Ron James,
told The Guardian (and anyone else
who cared to ask). 
Not everyone was swept away,
though. The New York Times, which
had gone hog wild over Dolly the
lamb, was much more circumspect
about the pigs, placing a dry story on
page 21, epitomized by lines like:
“Dr. David Ayares…said yesterday
that he hoped the announcement
would attract investors.” London’s
Daily Mail backed into the news
with this headline: “Are the
scientists risking a new BSE?” and
claiming that the “announcement
triggered a storm of controversy”,
although it looked more like a
localized squall directly over the
newspaper in question. 
To be sure, as the week
progressed, journalists started to
wonder more loudly whether
cloning a pig really burst the dam
that has been holding back
xenotransplantation. “Most
overblown and misleading is the
PPL claim that with its success at
cloning pigs, ‘all the known
technical hurdles to cross-species
transplants have been overcome’ ,”
The Los Angeles Times declared in an
editorial. “Actually, scientists are far
from mastering the very complex
procedures that will be necessary to
prevent human immune systems
from rejecting organs from pigs or
any other species,” it continued.
The Washington Post, which had
splashed the story across page 1
initially, came back five days later
with a more studious story headlined,
“In Organ Quest, Cloning Pigs May
Be the Easy Part.” This time, readers
were treated to a walk through the
world of H transferase and a 1-3
galactose, as they discovered that pig
organs for transplants aren’t likely to
rumble off the assembly line like so
many Virginia hams, at least not
anytime soon. 
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